a16zMark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease
CHAPTERS
Big ambition, real gap: biology needs a “periodic table” moment
Mark Zuckerberg frames AI as massive leverage for biology, but argues the field lacks foundational shared references—an equivalent of a periodic table for biological systems. Priscilla Chan recalls early skepticism about their “cure and prevent disease” mission, setting up the core thesis: tools, not just grants, are the unlock.
Why CZI focuses on tool-building to accelerate basic science
Zuckerberg explains that major scientific breakthroughs often follow new instruments that let researchers observe and measure differently (microscope/telescope analogy). CZI’s strategy is to build enabling tools and infrastructure that raise the overall velocity of basic science, filling a gap left by typical grant funding.
A credible pathway: from “fund more labs” to “build shared platforms”
Chan describes how the initial disease-curing mission forced a practical question: what blocks a credible path to progress? The answer they heard repeatedly was missing shared tools, datasets, and large coordinated efforts—leading CZI toward building platforms others can use and extend.
Biohub’s positioning: frontier biology + frontier AI (closing the gap)
They articulate the Biohub as a rare organization trying to do cutting-edge AI and cutting-edge biology together, rather than in separate silos. AlphaFold is cited as a proof point for AI impact—yet also evidence that better purpose-built biological datasets are needed to train next-generation models.
Working on 10–15 year horizons: choosing problems with a visible path
The conversation turns to why Biohub emphasizes “grand challenges” in a 10–15 year window—long enough to build deep platforms, but concrete enough to maintain momentum and credibility. Chan highlights their criteria: a credible path, strong leadership, and enough ambiguity to justify risk-taking.
Biohub network strategy: three sites, each building different biological capabilities
Chan outlines the three Biohubs and how each is oriented to a different layer of biology and measurement. The locations tie to partner universities and are designed for interdisciplinary collaboration, leveraging local academic strengths while operating outside traditional lab constraints.
Making sense of science with LLMs + defining “success” in therapeutics
They describe how LLMs changed what’s possible: once you can generate large datasets, the next challenge is interpreting them. In therapeutics, Chan defines success as enabling an ecosystem that can connect variants to downstream effects and then to precise targets—powering the next wave of precision medicine.
“Most diseases are rare diseases”: reframing personalization and diagnosis
Chan argues that common disease labels hide many distinct biological subtypes—making “rare disease thinking” broadly applicable. Current care often relies on trial-and-error; their vision is rapid, individualized treatment guided by a person’s unique biology.
Cell by Gene and the Cell Atlas: a network-effect platform for biology data
They explain how Cell by Gene began as an annotation workflow fix for single-cell data, then became a de facto standard. Standardized tooling led to standardized formats and community contribution—creating a shared Cell Atlas at scale, mostly funded by the broader ecosystem rather than CZI alone.
Why virtual cells: building a hierarchical “world model” of biology
Zuckerberg lays out the “virtual cell” as the next major tool: models spanning proteins, cell structures, and higher-order systems like the immune system. The aim is to generate hypotheses, simulate perturbations, and progressively combine specialized models into a more general biological simulator useful to researchers and (downstream) drug developers.
De-risking science: virtual biology enables bolder experimentation
Chan emphasizes that wet-lab work is slow and expensive, and grant/tenure incentives discourage high-risk ideas. Virtual models could shift exploration into silico, allowing researchers to test riskier hypotheses cheaply and quickly before committing lab resources.
What the models look like: variant prediction, diffusion-generated cells, and reasoning
They describe early model types: predicting outcomes of CRISPR edits, generating synthetic cell states via diffusion models, and an emerging “reasoning model over biology.” The long-run plan is hierarchical: best-in-class protein models feed into cellular models, which then extend to complex systems like the immune system.
The Biohub master plan: unify CZI + Biohub into one operating flywheel
They announce organizational consolidation: bringing datasets, instrumentation, and AI modeling into a single operating philanthropy under unified leadership (Alex Reeves). The goal is a tight feedback loop where model gaps inform new experiments and datasets, and new datasets rapidly improve models—closing the “data ↔ model” loop.
Democratizing discovery: interface design, collaboration, compute, and what’s next for AI in biotech
They argue that usability and interfaces are critical: tools should be accessible to non-experts and cross-disciplinary scientists to invite broader participation. They highlight Biohub’s collaboration model (co-locating disciplines), the shift toward compute as “new lab space,” shared GPU programs, and a forward-looking view that AI will accelerate biotech by enabling better tools and faster basic science translation.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome